Biotech Values

[DewDiligence]

PDUFA date for PFE’s “Prevnar 20”—>Jun 2021—(with_priority_review):

https://finance.yahoo.com/news/u-fda-accepts-priority-review-213000285.html

Prevnar 20 is the slated successor to PFE’s blockbuster pneumococcal vaccine, Prevnar 13—with protection against 7 additional serotypes.

Prevnar 20 will compete against MRK’s 15-serotype V114, which is currently under FDA review for adult patients (#msg-159660054). The emerging market for state-of-the-art pneumococcal vaccines seems destined to be “winner takes all,” which implies that the economic stakes for PFE and MRK are enormous.

The BLA described above pertains to adult patients. PFE plans a separate BLA in the pediatric setting. See #msg-154634395 for related info.